Apixaban bests rivaroxaban in lowering rates of recurrent VTE and bleeding: Study

From 1 January 2015 to 30 June 2020, a retrospective new-user cohort study was conducted in a commercial health care insurance database in the United States. Adults with VTE who had recently been prescribed apixaban or rivaroxaban were recruited for this study. The primary efficacy outcome was recurrent VTE, which was a combination of deep venous thrombosis and pulmonary embolism. The primary safety outcome was a combination of GI and intracranial bleeding.

The results stated the following:

1. Of the 49 900 eligible patients with VTE, 18 618 were new apixaban users and 18 618 were new rivaroxaban users.

2. The median follow-up time for apixaban users was 102 days (25th, 75th percentiles: 30, 128 days) and 105 days (25th, 75th percentiles: 30, 140 days) for rivaroxaban users.

3. Apixaban (vs. rivaroxaban) was associated with a lower rate of recurrent VTE and bleeding after propensity score matching.

4. The absolute reduction in the risk of recurrent VTE with apixaban versus rivaroxaban was 0.006 (CI, 0.005 to 0.011) after 2 months and 0.011 (CI, 0.011 to 0.013) after 6 months.

5. The absolute reduction in the risk of gastrointestinal and intracranial bleeding with apixaban versus rivaroxaban was 0.011 (CI, 0.010 to 0.011) after 2 months and 0.015 (CI, 0.013 to 0.015) after 6 months.

In conclusion, this study reveals the effectiveness of apixaban over rivaroxaban and how its much more significant in lowering the VTE. further research and data is needed to get rock solid evidence as it was a short follow up study.

Reference:

Ghadeer K. Dawwas, Charles E. Leonard, James D. Lewis, et al. Risk for Recurrent Venous Thromboembolism and Bleeding With Apixaban Compared With Rivaroxaban: An Analysis of Real-World Data. Ann Intern Med. [Epub ahead of print 7 December 2021]. doi:10.7326/M21-0717